202 Users Online
Liquid Pediatric Market Segmented By age group such as Infants, Child, Adolescent with dosage form in Solutions, Suspensions and Emulsions
Pediatric population is more vulnerable to several seasonal diseases such as respiratory and gastrointestinal conditions. Oral liquid formulations are mostly used dosage forms in pediatric patients to treat several seasonal and non-seasonal diseases. Recent data of Centers for Disease Control and Prevention (CDC) shows that hay fever or respiratory allergy occurs in around 15.2% of U. S. children population in 2017.
In age groups especially from 6 months to 12 years there is a certain limitations like swallowing solid dosage forms. Fast systemic absorption, ease of administration and acceptability is expected to increase the demand of liquid pediatric formulations in the global market.
Solution, suspension, emulsion along with wide range of flavors are the popular liquid pediatric dosage forms used to administered therapeutics in pediatrics. There has been a vast growth in pediatric clinical trials for new drugs enabling better availability of dosage forms for pediatrics especially liquid formulations.
Liquid pediatric formulations market is expected to grow at a higher rate due to rise in pediatric population in the emerging regions. Also increasing industrial clinical research on pediatrics by leading pharmaceutical companies is expected to increase demand of liquid pediatric formulation in the future.
Seasonal respiratory diseases in developing regions is expected to drive the growth of liquid pediatric formulations market. However, alternative novel delivery technologies and poor healthcare systems in developing countries expected to hamper the market growth in the future.
|Based on age group||
|Based on dosage form||
|Based on application||
|Based on distribution channels||
The key players operating in the global liquid pediatric formulations market are: Novartis AG, Merck & Co., Inc, Pfizer Inc., GlaxoSmithKline plc, Sanofi S.A., Astrazeneca plc, Boehringer Ingelheim International GmbH, Piramal Enterprises Ltd, Novo Nordisk A/S, AbbVie Inc and others.